POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Regeneron announced positive Phase 2 PINNACLE trial results for baloncibart, a first-in-class NPR1-blocking antibody, in postural orthostatic tachycardia syndrome (POTS), a condition with no FDA-approved treatments. A single 450 mg dose reduced the standing heart-rate response versus placebo by an LS mean difference of -11.4 bpm at day 8 (nominal p=0.0007) and -7.4 bpm at day 29, and improved orthostatic symptoms and physical functioning on the LWPQ questionnaire. The 150 mg dose showed a day-8 effect that was not maintained at day 29.
Key figures
- Drug Name
- baloncibart (REGN7544)
- Phase Of Trial
- Phase 2
- Trial enrollment
- 82
- Us pots prevalence
- 500,000 to several million
- Planned phase3 timing
- first half of 2027
- Primary endpoint p value
- 0.0007
- Day29 ls mean difference bpm
- -7.4
- Primary endpoint ls mean difference bpm
- -11.4
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.